Desirée Thielke
Publications by Year
Research Areas
Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Diabetes Management and Research, Diabetes Management and Education, Gastric Cancer Management and Outcomes
Most-Cited Works
- → Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial(2019)348 cited
- → Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial(2019)276 cited
- → Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial(2020)141 cited
- → Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden(2020)85 cited
- → Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: A model‐based approach(2018)32 cited
- → Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden(2020)26 cited
- → Semaglutide Reduces Body Weight Across Baseline BMI Subgroups Across SUSTAIN 1–5(2017)8 cited
- → Semaglutide provides superior glycemic control across SUSTAIN 1–5 clinical trials(2018)7 cited
- → Prototype of an evidence‐based tool to aid individualized treatment for type 2 diabetes(2021)6 cited
- [Orphan drugs--medications for patients with rare diseases].(2006)